Last reviewed 2026-05-14 · How we verify

injection of placebo of L-Dopa

University Hospital, Toulouse · Phase 3 active Small molecule

injection of placebo of L-Dopa is a Small molecule drug developed by University Hospital, Toulouse. It is currently in Phase 3 development for Control arm in Phase 3 trial (likely Parkinson's disease, based on L-Dopa comparator).

This is a placebo injection with no active pharmacological mechanism.

This is a placebo injection with no active pharmacological mechanism. Used for Control arm in Phase 3 trial (likely Parkinson's disease, based on L-Dopa comparator).

At a glance

Generic name	injection of placebo of L-Dopa
Sponsor	University Hospital, Toulouse
Modality	Small molecule
Therapeutic area	Neurology
Phase	Phase 3

Mechanism of action

As a placebo control, this injection contains no active drug substance and produces no direct molecular or physiological effect. It is used in clinical trials as a control arm to measure the effect of active L-Dopa treatment by comparison. Any observed effects in the placebo group are attributed to placebo response, natural disease progression, or other non-pharmacological factors.

Approved indications

Control arm in Phase 3 trial (likely Parkinson's disease, based on L-Dopa comparator)

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

injection of placebo of L-Dopa CI brief — competitive landscape report
injection of placebo of L-Dopa updates RSS · CI watch RSS
University Hospital, Toulouse portfolio CI

Frequently asked questions about injection of placebo of L-Dopa

What is injection of placebo of L-Dopa?

injection of placebo of L-Dopa is a Small molecule drug developed by University Hospital, Toulouse, indicated for Control arm in Phase 3 trial (likely Parkinson's disease, based on L-Dopa comparator).

How does injection of placebo of L-Dopa work?

This is a placebo injection with no active pharmacological mechanism.

What is injection of placebo of L-Dopa used for?

injection of placebo of L-Dopa is indicated for Control arm in Phase 3 trial (likely Parkinson's disease, based on L-Dopa comparator).

Who makes injection of placebo of L-Dopa?

injection of placebo of L-Dopa is developed by University Hospital, Toulouse (see full University Hospital, Toulouse pipeline at /company/university-hospital-toulouse).

What development phase is injection of placebo of L-Dopa in?

injection of placebo of L-Dopa is in Phase 3.

Manufacturer: University Hospital, Toulouse — full pipeline
Therapeutic area: All drugs in Neurology
Indication: Drugs for Control arm in Phase 3 trial (likely Parkinson's disease, based on L-Dopa comparator)
Compare: injection of placebo of L-Dopa vs similar drugs
Pricing: injection of placebo of L-Dopa cost, discount & access